Summit Therapeutics (SMMT)

• Market cap: $14.1B
• 1 day: 1.83%
• 5 days: -12.03%
• 1 month: -26.27%
• 3 months: -6.05%
• 6 months: -4.87%
• Year to date: 3.22%
• 1 year: -30.9%
• 5 years: 488.2%
• 10 years: 64.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Employees: 159

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $126M | Put options by funds: $77.1M

62% more first-time investments, than exits

New positions opened: 73 | Existing positions closed: 45

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

12% more funds holding

Funds holding: 211 [Q1] → 237 (+26) [Q2]

10% more capital invested

Capital invested by funds: $1.89B [Q1] → $2.08B (+$193M) [Q2]

0.07% less ownership

Funds ownership: 13.25% [Q1] → 13.18% (-0.07%) [Q2]

11% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 74

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21
• Avg. target: $37
• High target: $50

7 analyst ratings

• positive: 6 86%
• neutral: 1 14%
• negative: 0 0%

HC Wainwright & Co. Mitchell S. Kapoor	$50	Buy Reiterated	8 Sep 2025
Guggenheim Brad Canino	$40	Buy Initiated	4 Sep 2025
JMP Securities Reni J. Benjamin	$40	Market Outperform Reiterated	3 Sep 2025
Piper Sandler Kelsey Goodwin	$21	Neutral Initiated	19 Aug 2025
Evercore ISI Group Cory Kasimov	$34	Outperform Maintained	12 Aug 2025